DUAL HER2 BLOCKADE - A NEW DIRECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER


I.P. Ganshina, E.V. Lubennikova, L.G. Zhukova

FSBI RORC n.a. N.N. Blokhin RAMS, Moscow
With the advent of trastuzumab, vector of the prognostic significance of tumor marker has been changed for the first time in oncology practice - patients with HER2- positive tumors, previously considered as the most unfavorable, currently have the best prognosis. HER2 blockade strategy has been so successful that now it is the most extensively studying direction in the treatment of breast cancer (BC). The combination of pertuzumab, trastuzumab and docetaxel as first-line therapy for metastatic breast cancer has increased the progression-free survival by 6 months, and the use of trastuzumab as a neoadjuvant therapy has allowed to achieve complete pathological remission in 63 % of cases. Trastuzumab in combination with lapatinib in patients with progression on trastuzumab-containing regimens, has allowed to increase overall survival by 4.5 months; trastuzumab in the neoadjuvant therapy in combination with paclitaxel has allowed to achieve complete pathological remission in 51 % of cases.

About the Autors


I.P. Ganshina - FSBI RORC n.a. N.N. Blokhin RAMS
E.V. Lubennikova - FSBI RORC n.a. N.N. Blokhin RAMS
L.G. Zhukova – PhD in Medical Sciences, Leading Researcher at the Department of chemotherapy and combined treatments FSBI RORC n.a. N.N. Blokhin RAMS; e-mail: 8 (495) 324-96-30


Similar Articles


Бионика Медиа